<p>Comerica Bank 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度将其在 Insmed, Inc.（NASDAQ:INSM - 免费报告）的持股减少了 95.5%。该公司在季度内出售了 154,467 股后，持有 7,337 股生物制药公司的股票。截至其最近的 SEC 文件，Comerica Bank 在 Insmed 的持股价值为 1,277,000 美元。</p>
<ul>
<li>罗素再平衡：3 只股票准备上涨</li>
</ul>
<p>其他对冲基金最近也对该公司的持仓进行了调整。CoreCap Advisors LLC 在第四季度新购入了约 27,000 美元的 Insmed 股份。GraniteShares Advisors LLC 在第四季度购买了价值 30,000 美元的 Insmed 新股份。CIBC 私人财富集团在第三季度将其在 Insmed 的股份增加了 42.1%。CIBC 私人财富集团现在持有 179 股生物制药公司的股票，价值 26,000 美元，此前在上个季度又购买了 53 股。Stone House Investment Management LLC 在第三季度新购入了价值 29,000 美元的 Insmed 股份。最后，SBI 证券有限公司在第三季度将其在 Insmed 的股份增加了 404.9%。SBI 证券有限公司现在持有 207 股生物制药公司的股票，价值 30,000 美元，此前在上个季度又购买了 166 股。</p>
<h2>Insmed 股价下跌 3.6%</h2>
<p>周五，INSM 的开盘价为 101.17 美元。该公司的流动比率为 3.83，速动比率为 3.54，债务与股本比率为 0.76。Insmed, Inc.的 12 个月低点为 64.85 美元，12 个月高点为 212.75 美元。该公司的 50 日简单移动平均线为 145.87 美元，200 日简单移动平均线为 165.46 美元。该股票的市值为 218.4 亿美元，市盈率为-17.60，贝塔值为 0.89。</p>
<ul>
<li>股票轮换正在进行：以下是未来的赢家</li>
</ul>
<p>Insmed（NASDAQ:INSM - 获取免费报告）最近在 5 月 7 日发布了季度财报。该生物制药公司报告季度每股收益（EPS）为-0.76，超出市场共识预期的-0.90，超出 0.14 美元。该公司季度收入为 3.0596 亿美元，而分析师预期为 3.0081 亿美元。Insmed 的净利润率为-144.44%，股本回报率为-121.03%。与去年同期相比，该公司的收入增长了 229.7%。在去年同期，该公司每股收益为-1.42 美元。整体来看，研究分析师预计 Insmed, Inc.在本财年将发布-2.41 的每股收益。</p>
<h2>Insmed 内部活动</h2>
<p>在其他 Insmed 新闻中，首席执行官 William Lewis 在 2 月 9 日的交易中出售了 13,396 股公司的股票。股票以 147.79 美元的平均价格出售，总价值为 1,979,794.84 美元。交易完成后，首席执行官直接持有 301,185 股公司股票，价值约为 44,512,131.15 美元。这代表其持股减少了 4.26%。该出售在与 SEC 的法律文件中披露，可以通过此链接访问。此外，内部人士 Michael Alexander Smith 在 3 月 30 日的交易中出售了 19,638 股公司的股票。股票以 150.98 美元的平均价格出售，总交易额为 2,964,945.24 美元。交易完成后，该内部人士持有 51,871 股公司的股票，价值约为 7,831,483.58 美元。这笔交易代表其持股减少了 27.46%。该出售的 SEC 文件提供了更多信息。内部人士在上个季度共出售了 174,589 股公司股票，价值 27,441,807 美元。内部人士持有公司股票的比例为 2.10%。</p>
<h2>关于 Insmed 的热门头条</h2>
<p>以下是本周影响 Insmed 的主要新闻：</p>
<ul>
<li>积极情绪：Insmed 报告第一季度每股收益为-0.76，超出预期，收入同比增长 229.7%，达到 3.06 亿美元。该公司还重申了 2026 年的主要商业目标，包括至少 10 亿美元的 BRINSUPRI 收入和 4.5 亿到 4.7 亿美元的 ARIKAYCE 收入。文章：Insmed 发布 2026 年第一季度财务结果并提供业务更新</li>
<li>积极情绪：加拿大皇家银行和富国银行的分析师下调了他们的目标价，但维持了看涨评级，表明他们仍然看到当前水平的显著上行空间。RBC 将目标价从 220 美元下调至 205 美元，富国银行将目标价从 177 美元下调至 160 美元。文章：Benzinga 关于 RBC 目标价下调的报道文章：The Fly 关于富国银行目标价下调的报道</li>
<li>中性情绪：Insmed 还强调了其管道和商业化努力的进展，包括 ARIKAYCE 的 ENCORE 研究结果积极，以及 TPIP 的 PALM-PAH 研究的启动。这些更新支持长期故事，但不太可能立即推动股价。文章：Insmed 2026 年第一季度财务结果和业务更新</li>
<li>消极情绪：由于第一季度销售低于预期，公司的 2026 年隐含收入指引低于市场共识，引发了对推出势头可能无法匹配投资者期望的担忧。文章：Insmed 第一季度盈利超预期，销售未达预期，股价暴跌 23%</li>
<li>消极情绪：第一季度费用的增加也对情绪造成了压力，市场评论指出，成本上升是投资者在财报后抛售股票的另一个原因。文章：Insmed 股价因第一季度费用上升而暴跌</li>
</ul>
<h2>华尔街分析师预测增长</h2>
<p>几位分析师对 Insmed 的股票进行了评论。Leerink Partners 在 3 月 24 日的研究报告中将 Insmed 的目标价从 210.00 美元上调至 215.00 美元，并给予该公司 “跑赢大盘” 的评级。Truist Financial 在 1 月 12 日的报告中为 Insmed 设定了 205.00 美元的目标价。HC Wainwright 在周五的研究报告中重申了对 Insmed 股票的 “买入” 评级。Raymond James Financial 在 4 月 10 日的报告中开始覆盖 Insmed 股票，给予 “跑赢大盘” 的评级和 200.00 美元的目标价。最后，Wells Fargo &amp; Company 在周五的报告中将 Insmed 的目标价从 177.00 美元下调至 160.00 美元，并对该股票设定了 “增持” 评级。两位研究分析师给予该股票 “强烈买入” 评级，二十二位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，Insmed 的平均评级为 “买入”，平均目标价为 211.86 美元。</p>
<p><strong>查看我们关于 Insmed 的最新股票报告</strong></p>
<h2>Insmed 公司简介</h2>
<p>（免费报告）</p>
<p>Insmed Incorporated 是一家生物制药公司，专注于开发和商业化针对罕见和严重疾病患者的治疗方案，特别强调难以治疗的肺部感染。公司总部位于新泽西州布里奇沃特，集中研发针对药物靶向递送技术和新型制剂，旨在改善治疗选择有限患者的临床结果。</p>
<p>该公司的主要上市产品是 ARIKAYCE（阿米卡星脂质体吸入悬液），这是一种经美国批准的抗生素阿米卡星的吸入脂质体制剂。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 Insmed 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Insmed 吗？</h2>
<p>在考虑 Insmed 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Insmed 并不在名单上。</p>
<p>虽然 Insmed 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

INSM

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

<p>Comerica Bank 已显著减少对 Insmed, Inc. 的持股，减少幅度达到 95.5%，在第四季度出售了 154,467 股，剩余 7,337 股，估值约为 128 万美元。其他对冲基金也调整了在 Insmed 的持仓。该公司的股票经历了波动，最近的交易价格为 101.17 美元。Insmed 报告的季度每股收益为 -0.76 美元，超出预期，营收同比增长 229.7%。分析师们的情绪不一，有些下调了目标价，但仍维持看涨评级</p>

<p>Comerica Bank lowered its holdings in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 95.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 7,337 shares of the biopharmaceutical company's stock after selling 154,467 shares during the quarter. Comerica Bank's holdings in Insmed were worth $1,277,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Comerica Bank 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度将其在 Insmed, Inc.（NASDAQ:INSM - 免费报告）的持股减少了 95.5%。该公司在季度内出售了 154,467 股后，持有 7,337 股生物制药公司的股票。截至其最近的 SEC 文件，Comerica Bank 在 Insmed 的持股价值为 1,277,000 美元。</p>
</div><ul>
<li>Russell Rebalance: 3 Stocks Ready to Move Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>罗素再平衡：3 只股票准备上涨</li>
</ul>
</div><p>Other hedge funds have also recently made changes to their positions in the company. CoreCap Advisors LLC acquired a new stake in Insmed during the fourth quarter worth about $27,000. GraniteShares Advisors LLC purchased a new stake in Insmed in the fourth quarter valued at $30,000. CIBC Private Wealth Group LLC grew its stake in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 53 shares in the last quarter. Stone House Investment Management LLC acquired a new stake in shares of Insmed in the third quarter valued at $29,000. Finally, SBI Securities Co. Ltd. grew its stake in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 166 shares in the last quarter.</p>
<div class="lb-trans"><p>其他对冲基金最近也对该公司的持仓进行了调整。CoreCap Advisors LLC 在第四季度新购入了约 27,000 美元的 Insmed 股份。GraniteShares Advisors LLC 在第四季度购买了价值 30,000 美元的 Insmed 新股份。CIBC 私人财富集团在第三季度将其在 Insmed 的股份增加了 42.1%。CIBC 私人财富集团现在持有 179 股生物制药公司的股票，价值 26,000 美元，此前在上个季度又购买了 53 股。Stone House Investment Management LLC 在第三季度新购入了价值 29,000 美元的 Insmed 股份。最后，SBI 证券有限公司在第三季度将其在 Insmed 的股份增加了 404.9%。SBI 证券有限公司现在持有 207 股生物制药公司的股票，价值 30,000 美元，此前在上个季度又购买了 166 股。</p>
</div><h2>Insmed Trading Down 3.6%</h2>
<div class="lb-trans"><h2>Insmed 股价下跌 3.6%</h2>
</div><p>INSM opened at $101.17 on Friday. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. Insmed, Inc. has a 12 month low of $64.85 and a 12 month high of $212.75. The firm's fifty day simple moving average is $145.87 and its 200 day simple moving average is $165.46. The stock has a market capitalization of $21.84 billion, a P/E ratio of -17.60 and a beta of 0.89.</p>
<div class="lb-trans"><p>周五，INSM 的开盘价为 101.17 美元。该公司的流动比率为 3.83，速动比率为 3.54，债务与股本比率为 0.76。Insmed, Inc.的 12 个月低点为 64.85 美元，12 个月高点为 212.75 美元。该公司的 50 日简单移动平均线为 145.87 美元，200 日简单移动平均线为 165.46 美元。该股票的市值为 218.4 亿美元，市盈率为-17.60，贝塔值为 0.89。</p>
</div><ul>
<li>Stock Rotation is Underway: Here are the Winners Moving Forward</li>
</ul>
<div class="lb-trans"><ul>
<li>股票轮换正在进行：以下是未来的赢家</li>
</ul>
</div><p>Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.14. The firm had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 121.03%. The company's revenue was up 229.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.42) EPS. As a group, research analysts anticipate that Insmed, Inc. will post -2.41 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Insmed（NASDAQ:INSM - 获取免费报告）最近在 5 月 7 日发布了季度财报。该生物制药公司报告季度每股收益（EPS）为-0.76，超出市场共识预期的-0.90，超出 0.14 美元。该公司季度收入为 3.0596 亿美元，而分析师预期为 3.0081 亿美元。Insmed 的净利润率为-144.44%，股本回报率为-121.03%。与去年同期相比，该公司的收入增长了 229.7%。在去年同期，该公司每股收益为-1.42 美元。整体来看，研究分析师预计 Insmed, Inc.在本财年将发布-2.41 的每股收益。</p>
</div><h2>Insider Activity at Insmed</h2>
<div class="lb-trans"><h2>Insmed 内部活动</h2>
</div><p>In other Insmed news, CEO William Lewis sold 13,396 shares of the company's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $147.79, for a total value of $1,979,794.84. Following the completion of the transaction, the chief executive officer directly owned 301,185 shares in the company, valued at approximately $44,512,131.15. This represents a 4.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael Alexander Smith sold 19,638 shares of the company's stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the transaction, the insider owned 51,871 shares of the company's stock, valued at approximately $7,831,483.58. This trade represents a 27.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 174,589 shares of company stock valued at $27,441,807 in the last quarter. Insiders own 2.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Insmed 新闻中，首席执行官 William Lewis 在 2 月 9 日的交易中出售了 13,396 股公司的股票。股票以 147.79 美元的平均价格出售，总价值为 1,979,794.84 美元。交易完成后，首席执行官直接持有 301,185 股公司股票，价值约为 44,512,131.15 美元。这代表其持股减少了 4.26%。该出售在与 SEC 的法律文件中披露，可以通过此链接访问。此外，内部人士 Michael Alexander Smith 在 3 月 30 日的交易中出售了 19,638 股公司的股票。股票以 150.98 美元的平均价格出售，总交易额为 2,964,945.24 美元。交易完成后，该内部人士持有 51,871 股公司的股票，价值约为 7,831,483.58 美元。这笔交易代表其持股减少了 27.46%。该出售的 SEC 文件提供了更多信息。内部人士在上个季度共出售了 174,589 股公司股票，价值 27,441,807 美元。内部人士持有公司股票的比例为 2.10%。</p>
</div><h2>Trending Headlines about Insmed</h2>
<div class="lb-trans"><h2>关于 Insmed 的热门头条</h2>
</div><p>Here are the key news stories impacting Insmed this week:</p>
<div class="lb-trans"><p>以下是本周影响 Insmed 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Insmed reported Q1 EPS of -$0.76, beating estimates, and revenue rose 229.7% year over year to $306 million. The company also reiterated major 2026 commercial goals, including at least $1 billion in BRINSUPRI revenue and $450 million to $470 million in ARIKAYCE revenue. Article: Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update</li>
<li>Positive Sentiment: Analysts at Royal Bank of Canada and Wells Fargo cut their price targets but kept bullish ratings, signaling they still see meaningful upside from current levels. RBC lowered its target to $205 from $220 and Wells Fargo cut to $160 from $177. Article: Benzinga report on RBC price target cutArticle: The Fly report on Wells Fargo price target cut</li>
<li>Neutral Sentiment: Insmed also highlighted progress on its pipeline and commercialization efforts, including positive ENCORE study results for ARIKAYCE and the start of the PALM-PAH study for TPIP. These updates support the long-term story, but they are less likely to move the stock immediately. Article: Insmed Q1 2026 Financial Results and Business Update</li>
<li>Negative Sentiment: The stock is under pressure because Q1 sales came in below expectations and the company’s implied 2026 revenue guidance was below consensus, raising concerns that launch momentum may not be matching investor hopes. Article: Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%</li>
<li>Negative Sentiment: Higher first-quarter expenses also weighed on sentiment, with market commentary pointing to increased costs as another reason investors sold the shares after earnings. Article: Insmed Shares Tumble Amid Higher 1Q Expenses</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Insmed 报告第一季度每股收益为-0.76，超出预期，收入同比增长 229.7%，达到 3.06 亿美元。该公司还重申了 2026 年的主要商业目标，包括至少 10 亿美元的 BRINSUPRI 收入和 4.5 亿到 4.7 亿美元的 ARIKAYCE 收入。文章：Insmed 发布 2026 年第一季度财务结果并提供业务更新</li>
<li>积极情绪：加拿大皇家银行和富国银行的分析师下调了他们的目标价，但维持了看涨评级，表明他们仍然看到当前水平的显著上行空间。RBC 将目标价从 220 美元下调至 205 美元，富国银行将目标价从 177 美元下调至 160 美元。文章：Benzinga 关于 RBC 目标价下调的报道文章：The Fly 关于富国银行目标价下调的报道</li>
<li>中性情绪：Insmed 还强调了其管道和商业化努力的进展，包括 ARIKAYCE 的 ENCORE 研究结果积极，以及 TPIP 的 PALM-PAH 研究的启动。这些更新支持长期故事，但不太可能立即推动股价。文章：Insmed 2026 年第一季度财务结果和业务更新</li>
<li>消极情绪：由于第一季度销售低于预期，公司的 2026 年隐含收入指引低于市场共识，引发了对推出势头可能无法匹配投资者期望的担忧。文章：Insmed 第一季度盈利超预期，销售未达预期，股价暴跌 23%</li>
<li>消极情绪：第一季度费用的增加也对情绪造成了压力，市场评论指出，成本上升是投资者在财报后抛售股票的另一个原因。文章：Insmed 股价因第一季度费用上升而暴跌</li>
</ul>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several analysts have commented on INSM shares. Leerink Partners upped their price objective on Insmed from $210.00 to $215.00 and gave the company an &#34;outperform&#34; rating in a research note on Tuesday, March 24th. Truist Financial set a $205.00 price target on Insmed in a report on Monday, January 12th. HC Wainwright restated a &#34;buy&#34; rating on shares of Insmed in a research note on Friday. Raymond James Financial assumed coverage on shares of Insmed in a report on Friday, April 10th. They issued an &#34;outperform&#34; rating and a $200.00 target price on the stock. Finally, Wells Fargo &amp; Company dropped their target price on Insmed from $177.00 to $160.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Insmed has an average rating of &#34;Buy&#34; and an average target price of $211.86.</p>
<div class="lb-trans"><p>几位分析师对 Insmed 的股票进行了评论。Leerink Partners 在 3 月 24 日的研究报告中将 Insmed 的目标价从 210.00 美元上调至 215.00 美元，并给予该公司 “跑赢大盘” 的评级。Truist Financial 在 1 月 12 日的报告中为 Insmed 设定了 205.00 美元的目标价。HC Wainwright 在周五的研究报告中重申了对 Insmed 股票的 “买入” 评级。Raymond James Financial 在 4 月 10 日的报告中开始覆盖 Insmed 股票，给予 “跑赢大盘” 的评级和 200.00 美元的目标价。最后，Wells Fargo &amp; Company 在周五的报告中将 Insmed 的目标价从 177.00 美元下调至 160.00 美元，并对该股票设定了 “增持” 评级。两位研究分析师给予该股票 “强烈买入” 评级，二十二位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，Insmed 的平均评级为 “买入”，平均目标价为 211.86 美元。</p>
</div><p><strong>View Our Latest Stock Report on Insmed</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Insmed 的最新股票报告</strong></p>
</div><h2>Insmed Company Profile</h2>
<div class="lb-trans"><h2>Insmed 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.</p>
<div class="lb-trans"><p>Insmed Incorporated 是一家生物制药公司，专注于开发和商业化针对罕见和严重疾病患者的治疗方案，特别强调难以治疗的肺部感染。公司总部位于新泽西州布里奇沃特，集中研发针对药物靶向递送技术和新型制剂，旨在改善治疗选择有限患者的临床结果。</p>
</div><p>The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.</p>
<div class="lb-trans"><p>该公司的主要上市产品是 ARIKAYCE（阿米卡星脂质体吸入悬液），这是一种经美国批准的抗生素阿米卡星的吸入脂质体制剂。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Insmed</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Insmed 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=INSM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Insmed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Insmed 吗？</h2>
</div><p>Before you consider Insmed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Insmed 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Insmed 并不在名单上。</p>
</div><p>While Insmed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Insmed 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Comerica Bank Sells 154,467 Shares of Insmed, Inc. $INSM

Market Beat

Insmed

Comerica

加拿大帝国商业银行

加拿大皇家银行

SBI Holdings, Inc.

富国银行

COMERICA INC 6.875 % DEP PFD SER B

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Comerica 银行出售了 154,467 股 Insmed 公司的股票，股票代码为$INSM